|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
EP3311836A1
(en)
|
2005-04-08 |
2018-04-25 |
Wyeth LLC |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
PE20110072A1
(es)
*
|
2005-06-27 |
2011-02-04 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica
|
|
GB0607088D0
(en)
*
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
KR101515078B1
(ko)
|
2005-12-22 |
2015-04-24 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
|
ES2749952T3
(es)
|
2008-12-18 |
2020-03-24 |
Wyeth Llc |
Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
|
|
BRPI0922981A8
(pt)
|
2008-12-18 |
2019-11-26 |
Wyeth Llc |
método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
|
|
EP2411048B1
(en)
|
2009-03-24 |
2020-05-06 |
GlaxoSmithKline Biologicals SA |
Adjuvanting meningococcal factor h binding protein
|
|
EP3017826A1
(en)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
|
US20120052088A1
(en)
|
2009-04-30 |
2012-03-01 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
PL2575870T3
(pl)
|
2010-06-04 |
2017-05-31 |
Wyeth Llc |
Preparaty szczepionek
|
|
AU2011268507B2
(en)
|
2010-06-25 |
2014-08-14 |
Novartis Ag |
Combinations of meningococcal factor H binding proteins
|
|
WO2012117377A1
(en)
|
2011-03-02 |
2012-09-07 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
|
JP2015505309A
(ja)
|
2011-12-29 |
2015-02-19 |
ノバルティス アーゲー |
髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
|
|
EP2822584A1
(en)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Combination vaccines with tlr4 agonists
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
JP6324961B2
(ja)
|
2012-09-06 |
2018-05-16 |
ノバルティス アーゲー |
血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
|
|
GB201218660D0
(en)
|
2012-10-17 |
2012-11-28 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US20150320852A1
(en)
|
2012-12-18 |
2015-11-12 |
Glaxosmithkline Biologicals Sa |
Conjugates for protecting against diphtheria and/or tetanus
|
|
CN110859957B
(zh)
|
2014-01-21 |
2024-04-12 |
辉瑞公司 |
包含缀合荚膜糖抗原的免疫原性组合物及其用途
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
PL3096786T3
(pl)
|
2014-01-21 |
2021-11-08 |
Pfizer Inc. |
Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
|
|
CN103893751B
(zh)
*
|
2014-03-26 |
2016-04-20 |
天津康希诺生物技术有限公司 |
一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
|
|
HUE062499T2
(hu)
|
2015-01-15 |
2023-11-28 |
Pfizer |
Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
|
|
MY182282A
(en)
|
2015-05-04 |
2021-01-18 |
Pfizer |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
CA3031799A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
CA3031797A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
US11951165B2
(en)
|
2016-12-30 |
2024-04-09 |
Vaxcyte, Inc. |
Conjugated vaccine carrier proteins
|
|
CN110366428B
(zh)
|
2016-12-30 |
2024-05-17 |
Vaxcyte公司 |
具有非天然氨基酸的多肽-抗原缀合物
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
EP4656208A3
(en)
|
2017-01-31 |
2026-03-04 |
Merck Sharp & Dohme LLC |
Methods for making polysaccharide-protein conjugates
|
|
JP7680185B2
(ja)
*
|
2017-02-24 |
2025-05-20 |
メルク・シャープ・アンド・ドーム・エルエルシー |
肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
|
|
WO2018227177A1
(en)
|
2017-06-10 |
2018-12-13 |
Inventprise, Llc |
Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
|
|
US10729763B2
(en)
|
2017-06-10 |
2020-08-04 |
Inventprise, Llc |
Mixtures of polysaccharide-protein pegylated compounds
|
|
MX394768B
(es)
|
2017-09-07 |
2025-03-21 |
Merck Sharp & Dohme Llc |
Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
|
|
CN111093650B
(zh)
|
2017-09-07 |
2024-03-01 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
|
MX394767B
(es)
|
2017-09-07 |
2025-03-24 |
Merck Sharp & Dohme Llc |
Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
|
|
ES3058336T3
(es)
|
2017-12-06 |
2026-03-10 |
Merck Sharp & Dohme Llc |
Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
|
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
|
BR112020014978A2
(pt)
|
2018-02-05 |
2020-12-22 |
Sanofi Pasteur, Inc. |
Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
|
|
EP3749357A4
(en)
|
2018-02-05 |
2022-04-20 |
Sanofi Pasteur, Inc. |
POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
|
|
EP3765516A2
(en)
*
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2020010000A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Improved methods for the preparation of immunogenic conjugates
|
|
DK3817775T3
(da)
|
2018-07-04 |
2024-09-16 |
Vaxcyte Inc |
Forbedringer i immunogene konjugater
|
|
WO2020010016A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Self-adjuvanted immunogenic conjugates
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
CN113227125A
(zh)
|
2018-12-12 |
2021-08-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于o-连接的糖基化的修饰的载体蛋白
|
|
CR20210333A
(es)
|
2018-12-19 |
2021-08-18 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
|
|
WO2020208502A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
|
PH12022550110A1
(en)
|
2019-07-31 |
2022-12-12 |
Sk Bioscience Co Ltd |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
|
JOP20200214A1
(ar)
|
2019-09-03 |
2021-03-03 |
Serum Institute Of India Pvt Ltd |
تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
|
|
US12473379B2
(en)
*
|
2019-09-06 |
2025-11-18 |
Serum Institute Of India Private Limited |
Method for obtaining purified bacterial polysaccharides
|
|
US20230000966A1
(en)
|
2019-11-01 |
2023-01-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
BR112022014555A2
(pt)
|
2020-02-23 |
2022-09-20 |
Pfizer |
Composições de escherichia coli e métodos das mesmas.
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
US12497640B2
(en)
*
|
2020-05-14 |
2025-12-16 |
Serum Institute Of India Private Limited |
Methods for simultaneous fragmentation and purification of bacterial polysaccharides
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
WO2021259743A2
(en)
|
2020-06-25 |
2021-12-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
WO2022035816A1
(en)
|
2020-08-10 |
2022-02-17 |
Inventprise, Llc |
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
|
|
KR20230056727A
(ko)
|
2020-08-26 |
2023-04-27 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
PE20231934A1
(es)
|
2020-10-27 |
2023-12-01 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas
|
|
CA3200602A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
JP7804673B2
(ja)
|
2020-11-10 |
2026-01-22 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
KR102610292B1
(ko)
*
|
2021-02-10 |
2023-12-04 |
에스케이바이오사이언스(주) |
스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
JP2024517780A
(ja)
|
2021-05-03 |
2024-04-23 |
ファイザー・インク |
細菌およびベータコロナウイルス感染症に対するワクチン接種
|
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
|
JP2024521847A
(ja)
|
2021-05-28 |
2024-06-04 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
CA3247998A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
|
|
WO2023192997A2
(en)
*
|
2022-03-31 |
2023-10-05 |
The Children's Medical Center Corporation |
Immunogenic compositions for b-cell recall response to a polysaccharide antigen
|
|
CA3256617A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
|
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
EP4622665A2
(en)
|
2022-11-22 |
2025-10-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2023403045A1
(en)
|
2022-12-01 |
2025-06-12 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
GB202302579D0
(en)
|
2023-02-23 |
2023-04-12 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
PE20252774A1
(es)
|
2023-03-30 |
2025-12-22 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
|
|
AU2024255922A1
(en)
|
2023-04-14 |
2025-10-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
KR20260015203A
(ko)
|
2023-05-19 |
2026-02-02 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025174398A1
(en)
|
2024-02-14 |
2025-08-21 |
Merck Sharp & Dohme Llc |
26-valent pneumococcal conjugate vaccines and methods of use thereof
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|